IMVT
Immunovant, Inc. Common Stock
stockNASDAQ
immunovant, inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. it develops imvt-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in phase iia clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as has completed initiation of phase ii clinical trials for the treatment of warm autoimmune hemolytic anemia. the company is headquartered in new york, new york. immunovant, inc. is a subsidiary of roivant sciences ltd.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 33.49 | 2026-09-28 | +0.28% | -0.626 |
| 1M | 39.25 | 2026-09-04 | -14.43% | 1.229 |
| 3M | 38.60 | 2026-07-06 | -12.99% | 0.473 |
| 6M | 24.89 | 2026-04-06 | +34.93% | 1.432 |
| 1Y | 16.90 | 2025-10-03 | +98.73% | 1.350 |
| 2Y | 30.51 | 2024-10-04 | +10.08% | — |
| 5Y | 8.78 | 2021-10-04 | +282.52% | 1.101 |
Immunovant, Inc. Common Stock (NASDAQ:IMVT) stock price today is $33.59, and today's volume is 1,022,191. IMVT is down 0.193% today. The 30 day average volume is 1.42M. IMVT market cap is $6.94B with 206.55M shares outstanding.